EFPIA - NEWSLETTER

Trouble reading this email? View it in your browser


		EFPIA Newsletter 30 January 2025

PFAS: Working toward a sustainable future while protecting patient care

Read the full article by Nathalie Moll, Director General, EFPIA

Over the past couple of years there has been a growing focus on PFAS (per- and poly-fluoroalkyl substances) — a group of more than 10,000 synthetic chemicals that are widely used in consumer and industrial products.

Their chemical stability and resistance to oil and water has made them incredibly useful across many industries, including the pharmaceutical sector, where they are critical to medicines and medical devices, manufacturing and packaging.

Following a joint REACH restriction proposal by five EU member states in 2023, this broad group of chemicals has been under the spotlight due to environment and health concerns, potentially concluding in a widespread ban on all PFAS by 2027.

EFPIA response to the European Commission’s ‘Competitiveness Compass’
29 January 2025

EFPIA welcomes the publication of the Competitiveness Compass and the recognition of the role that innovation in life... Read more

Medicine shortages: EFPIA proposal for action
29 January 2025

Together, all stakeholders share a responsibility and commitment to building resilient supply chains that ensure patients... Read more

EFPIA response to the adoption of the European Health Data Space (EHDS)
24 January 2025

EFPIA welcomes the adoption of the European Health Data Space (EHDS) by the Council of the EU, marking a significant... Read more

EU Health Coalition - Reshaping health for a stronger Europe

Health is fundamental to the wellbeing of individuals and families, and to our societies, economies and security. Well-performing health systems, a resilient health workforce and a strong footprint in research and innovation for life sciences are key for Europe to remain prosperous and competitive in a turbulent world.

Discover the EU Health Coalition's vision for health.

Vaccine Voices: What makes antimicrobial resistance such a significant public health threat?

Watch the new episode of the Vaccines Voices series where Charlie Weller from Wellcome discusses why antimicrobial resistance is a significant threat to public health.

Events

In conversation with... Beat-DKD and Hypo-Resolve
04 February 2025 (Online event)

People who have diabetes are also more likely to develop certain complications, such as hypoglycaemia and diabetic kidney... Read more

Cancer Care 2030: From policy ambition to impact
19 March 2025 (Brussels, Belgium)

Join us on 19 March in Brussels to discuss how we can work together to accelerate progress to improve cancer care Read more

What we are reading

Video Interview: Claus Zieler of Astellas and EFPIA
On 29 January 2025 (The Medicine Maker)

In Europe, new medicines are often very slow to come to market because of fragmentation. The region is also no longer... Read more

European Shortages Monitoring Platform fully operational for monitoring of shortages in the...
On 29 January 2025 (European Medicines Agency)

The European Shortages Monitoring Platform (ESMP) is now live with the full scope of functionalities. This will enable marketing... Read more

About the EFPIA newsletter

The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. Through its direct membership of 37 national associations and 40 leading pharmaceutical companies, EFPIA is the voice on the EU scene of 1,900 companies committed to researching, developing and bringing to patients new medicines that will improve health and the quality of life around the world.

Tel: +32 (0)2 626 25 55
E-mail:Communications@efpia.eu